Organicell Regenerative Stock Rockets 325% On As FDA Approves Two Emergency INDs
The coronavirus pandemic has seen a mad rush among many companies to come up with therapies, medicines, and vaccines. Consequently, many of those companies have also seen their stocks soar to new heights on the back of heightened optimism. One of the companies that had a good day on Thursday was Organicell Regenerative Medicine, Inc. (OTCBB: BPSR).
The clinical-stage biopharmaceutical company announced on Thursday that it got approval for two Emergency Investigational New Drug Applications from the United States Food and Drug Administration. The two medicines in question are meant for treating patients who are suffering from mild to moderate respiratory difficulties brought about by COVID 19.
It is a major milestone for the company and opens up a world of opportunities. The market recognized the significance of the announcement as well and soon enough the stock started climbing. On Thursday, the Organicell stock rallied by as much as 325% and it remains to be seen if it can add to those gains on Friday. It goes without saying that investors could consider keeping an eye on the stock over the coming days.
It emerged that the first patient who had been approved for emergency treatment had been suffering from respiratory problems but after being administered with three doses of Organicell Flow, the situation improved considerably. These are major developments and it remains to be seen if the company can capitalize on it to makes its products more popular.
There is still no end in sight to the coronavirus pandemic and hence, it could these pair of medicines from Organicell could yet prove to be a big boost to the company.
However, that is not all. In this regard, it is necessary for investors to also take a closer look at some of the events that took place a few months ago. This was not the first time that one of its products got a significant boost. Back in early May, the FDA had approved the company’s application for Investigational New Drug for its lead product Organicell Flow. At the time, the application had been made for the drug to be seen as a possible treatment for patients who are suffering from moderate to severe respiratory problems arising out of COVID 19 infection.
At the time, the Chief Executive Officer of the company Albert Mitrani had stated that the approval of the application was a major step in the company’s quest to become a global leader in regenerative medicines. He went on to state that while the company was going to work on the FDA clinical trial for Organicell Flow, the company was going to continue its work with regards to the other medicines in its pipeline.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.